Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Commodity Prices Are Rising, That’s Why Full Drug Re-Pricing Needed in 2023: MOF Official
October 25, 2022
- Moderna’s BA.4/5 COVID Jab Up for PAFSC Review on Oct. 31
October 25, 2022
- Early Approval, Reimbursement of SaMD Put on Priority Agenda: Deregulation Panel
October 25, 2022
- Japan Might Change Timing of Drug Price Revisions from April amid Medical DX Push
October 24, 2022
- Nearly 700 Key Drugs Found to Be Unprofitable Due to Inflation, FX: Survey
October 24, 2022
- Is New Expert Panel All about Drug Pricing System? Asks Chair
October 24, 2022
- Experts Call for Debate on Scope of Health Coverage, “Exit Rule” for Unnecessary Meds
October 24, 2022
- PMDA Reviewing New Safety Risks for Evrenzo and More Drugs
October 24, 2022
- With Shortened Interval, Omicron Booster Likely to Cover 18 Million More People by Month-End
October 21, 2022
- LDP Project Team to Present Proposal for FY2023 Drug Price Revision and Budget Planning
October 21, 2022
- COVID Booster Interval to Be Shortened to “At Least 3 Months”
October 20, 2022
- Silgard 9’s Label Updated to Add Long-Term Follow-Up Study Data
October 19, 2022
- Avigan Secured for COVID-19 to Be Stockpiled for Pandemic Flu: Health Minister
October 19, 2022
- Label Expansions for TS-1, Enhertu on PAFSC Agenda on Oct. 31
October 18, 2022
- Japan Panel Recognizes One More Death Possibly Linked to COVID Jab
October 18, 2022
- Health Ministry Research Team to Vet Recall Rules to Address Supply Disruptions
October 17, 2022
- Include COVID Drug R&D Support in New Economic Package: LDP Health Panel
October 17, 2022
- Pfizer’s Precedex Up for PAFSC Review for Pediatric Indication as Japan’s 1st “Specific Use Drug” on Oct. 28
October 17, 2022
- Japan to Prepare Schedule for DX in Medical Fee Revisions by Next Spring
October 14, 2022
- Lawmakers Call for Starting 9-Valent HPV Vaccination Program in April 2023
October 14, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…